Product name:Linagliptin
CAS:668270-12-0
Molecular Formula:C25H28N8O2
Formula Weight:472.54g/mol
Description:The low therapeutic dose of linagliptin, the long-lasting inhibition of DPP-4 activity and the good safety/tolerability profile exhibited thus far suggest that linagliptin may be superior to competitors. The results from ongoing phase III clinical trials will provide further information on such aspects; however, from the available data, linagliptin appears to have promise for market success.
没有评论:
发表评论